RxDoctor Payments Data

Kara Trlica

Family · Cranbury, NJNPI 1992816813

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $117,875 of the $185,699 with a category attached, or 63.5%. Novartis accounts for 74.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $107,328 and has fallen 71.2% since, to $30,902 in 2024. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$185,699in general payments, 2019–2025

Across 157 payments — averaging $1182.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$137K
  • Gilead$47K
  • AstraZeneca$371
  • Merck$192
  • Amgen$148
  • Novocure Inc.$130
  • plus $280 from 5 others

What the payments were for

  • Consulting fees$117,87563%
  • Speaking & faculty fees$36,49320%
  • Travel & lodging$28,70115%
  • Food & beverage$2,5311%
  • Education$1000%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$185,699 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Other family in Cranbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →